Albemarle (ALB) Proxy Filing summary

Executive summary

• Achieved $5.1B in net sales and $1.1B adjusted EBITDA in 2025, with 7% volume growth and $450M in cost/productivity improvements, exceeding targets.

• Operating cash flow rose 86% to $1.3B, driven by cost reductions, working capital management, and a $350M customer prepayment.

• Divested controlling interests in Ketjen and Eurecat JV, receiving $670M in proceeds to reduce debt and support growth.

• Board appointed two new independent directors in 2026, enhancing expertise and aligning with strategic priorities.

• Maintained industry leadership through disciplined execution, portfolio management, and financial flexibility.

Voting matters and shareholder proposals

• Proposals include election of 10 directors, advisory vote on executive compensation, ratification of PwC as auditor, Charter amendment to remove supermajority provisions, approval of 2026 Incentive Plan, and a shareholder proposal on special meetings.

• Board recommends FOR all management proposals and AGAINST the shareholder proposal on special meetings.

• Charter amendment seeks to eliminate remaining supermajority voting requirements for affiliated transactions.

• Shareholder proposal requests 10% ownership threshold for calling special meetings; Board prefers 15–25% threshold and further engagement.

Board of directors and corporate governance

• Board consists of 10 nominees, 9 of whom are independent, with an average tenure of 6.9 years and diverse expertise.

• Annual election of directors, robust independence standards, and regular board/committee evaluations.

• Proxy access allows shareholders (3% ownership for 3 years) to nominate up to 20% of the Board.

• Lead Independent Director role with substantive responsibilities; regular executive sessions of independent directors.

• Board committees: Audit & Finance, Executive Compensation & Talent Development, Governance & Public Policy, Safety, Sustainability, Operations & Capital.